Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sean Webster

Physician Assistant, Medical Bountiful, UT Physician Assistant

NPI 1063759215 CMS profile 10716040

557 W 2600 S, Bountiful, UT 84010

Open in the dashboard

General payments

$8,917

579 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sean Webster of Bountiful, UT is reported in the CMS Open Payments database as having received $8,917 across 579 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,933 117
2024 General $1,620 92
2023 General $1,861 119
2022 General $1,845 119
2021 General $1,659 132

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sean Webster
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Sean Webster were reported at $1,933. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Sean Webster Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,659 $156 $41–$563 $132
2022 $1,845 $185 $55–$649 $149
2023 $1,861 $199 $58–$717 $160
2024 $1,620 $206 $62–$740 $164
2025 $1,933 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,565 108 payments
  2. AstraZeneca Pharmaceuticals LP $857 33 payments
  3. Lilly USA, LLC $774 59 payments
  4. Novo Nordisk Inc $734 62 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $624 28 payments
  6. GlaxoSmithKline, LLC. $532 37 payments
  7. Amgen Inc. $519 45 payments
  8. Astellas Pharma US Inc $245 13 payments
  9. Amarin Pharma Inc. $218 24 payments
  10. ITI, Inc. $218 12 payments
  11. Other $2,630 158 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,892 578 payments
  2. Education $25 1 payment
Products named General payments · program years 2021–2025
  1. VRAYLAR $782 58 payments
  2. FARXIGA $644 19 payments
  3. BREZTRI $587 13 payments
  4. Ozempic $499 42 payments
  5. RYBELSUS $477 41 payments
  6. MOUNJARO $474 36 payments
  7. TRADJENTA $380 17 payments
  8. AIRSUPRA $295 6 payments
  9. JARDIANCE $287 22 payments
  10. SHINGRIX $273 18 payments
  11. Other $7,894 516 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 72 drugs

Part D claims

3,238

Median for Physician Assistant: 241

Drug cost

$274,941

Median for Physician Assistant: $4,110

Branded share of claims

17.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 42 $50,988
Farxiga Dapagliflozin Propanediol Brand 37 $39,422
Ozempic Semaglutide Brand 30 $38,483
Eliquis Apixaban Brand 23 $31,861
Jardiance Empagliflozin Brand 35 $29,481
Xarelto Rivaroxaban Brand 14 $20,476
Myrbetriq Mirabegron Brand 15 $11,199
Xigduo Xr Dapaglifloz Propaned/Metformin Brand 13 $7,345
Atorvastatin Calcium Generic 278 $3,083
Omeprazole Generic 110 $2,321

The 10 drugs with the highest cost, of 72 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$22,049

Of which drugs: $3,323

Medicare patients

80

Average age 71

Services billed

473

17 women, 63 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 41%
Diabetes 29%
Chronic kidney disease 24%
Atrial fibrillation 21%
Depression 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 26 26 $2,127

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $188
$188 — —
MOUNJARO
  • Lilly USA, LLC $116
$116 42 —
Veozah
  • Astellas Pharma US Inc $110
$110 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $102
$102 — —
Korlym
  • Corcept Therapeutics $88
$88 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

579 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record